Mentor receives FDA approval for synthetic mesh product for pelvic organ prolapse

By Lisa Kerner

Erie, Pa., April 21 - The Food and Drug Administration granted U.S. marketing approval to Mentor Corp. for NovaSilk, its first synthetic mesh product for the treatment of pelvic organ prolapse, a non-life threatening condition affecting 40% of women over age 50.

Pelvic organ prolapse occurs when the pelvic floor muscles become weak or damaged and can no longer support the pelvic organs, according to a company news release.

NovaSilk, a lightweight mesh comprised of a knitted, monofilament polypropylene, can be used for other pelvic floor procedures, including cystocele, enterocele, rectocele and vaginal vault prolapse procedures.

Located in Santa Barbara, Calif., Mentor is a supplier of medical products for the aesthetics, urologic specialties and clinical and consumer health care markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.